NCT06754865Not yet recruiting
Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
A Muulticenter, Open, Non-interventional, Retrospective Cohort Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
Source: ClinicalTrials.gov · Last updated 1 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to provide guidance and basis for the clinical application of Xiyanping injection combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease.The secondary objectives is to evaluate the effect of Xiyanping injection on the indicators of acute exacerbation of inflammation and symptom improvement of chronic obstructive pulmonary disease.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1140 (estimated)
- First submitted
- 15 Dec 2024
- Start date
- Dec 2024
- Primary completion date
- Nov 2025
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Diseases
- COPD
- NCT number
- NCT06754865
What you commit to
- Study type: Observational
- Planned participants: 1140
- From Dec 2024 to the primary completion date, Nov 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with viral pneumonia or other systemic infection (such as urinary tract infection);
Other
- Researchers believe that multiple proprietary Chinese medicines with the same or similar functions (such as Tanreqing injection, Reduning injection, Yanhuning injection, etc.) have been used at the same time during treatment, resulting in no assessment of efficacy or safety;
- Patients who do not use intravenous antibiotics;
- Refuse the case to be used by researchers.
Who the study is looking for
- Discharged with chronic obstructive pulmonary disease;
- Hospitalized patients with COPD or AECOPD combined with lower respiratory tract infection;
- The treatment course of Xiyanping injection in the exposed group was ≥3 days, and the non-exposed group did not use Xiyanping injection;
- Study patients with complete medical records.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.